92 related articles for article (PubMed ID: 25017896)
1. Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study.
Palumbo B; Sivolella S; Palumbo I; Buresta T; Radicchia V; Fravolini ML; Ferretti F; Bellavita R; Mearini L; Scialpi M; Aristei C; Pelliccia G
Q J Nucl Med Mol Imaging; 2016 Dec; 60(4):397-403. PubMed ID: 25017896
[TBL] [Abstract][Full Text] [Related]
2. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
4. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
5. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
6. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
[TBL] [Abstract][Full Text] [Related]
8. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
[TBL] [Abstract][Full Text] [Related]
10. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
11. Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?
Di Biagio D; Chiaravalloti A; Tavolozza M; Abbatiello P; Schillaci O
Ann Nucl Med; 2015 Dec; 29(10):861-9. PubMed ID: 26261000
[TBL] [Abstract][Full Text] [Related]
12. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
[TBL] [Abstract][Full Text] [Related]
14. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
17. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
18. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
Schiavina R; Scattoni V; Castellucci P; Picchio M; Corti B; Briganti A; Franceschelli A; Sanguedolce F; Bertaccini A; Farsad M; Giovacchini G; Fanti S; Grigioni WF; Fazio F; Montorsi F; Rigatti P; Martorana G
Eur Urol; 2008 Aug; 54(2):392-401. PubMed ID: 18456393
[TBL] [Abstract][Full Text] [Related]
19. Detectability of 18F-choline PET/MR in primary hyperparathyroidism.
Araz M; Nak D; Soydal Ç; Peker E; Erden İ; Küçük NÖ
Eur Arch Otorhinolaryngol; 2022 May; 279(5):2583-2589. PubMed ID: 34495350
[TBL] [Abstract][Full Text] [Related]
20. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
